Global Angiotensin II Receptor Blockers (ARBs) Market, By Type (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan), Application (Hypertension, Heart Failure, High Blood Pressure, Kidney Disease, Others), End-Users (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Angiotensin II Receptor Blockers (ARBs) Market
Global angiotensin II receptor blockers (ARBs) market is estimated to gain market growth in the upcoming forecast years. Data Bridge Market Research analyses that the market is growing at a CAGR of 7.80% in the above-mentioned research forecast period. Increasing prevalence and incidence of hypertension, cardiovascular and kidney disease will drive the market growth.
The demand of angiotensin II receptor blockers (ARBs) market has increased significantly because of advancements in technology, high prevalence and incidence of cardiovascular and kidney disease, and increasing aged population will boost the market growth. Moreover, increasing patient population, technological advancements and lack of efficient treatment will act as opportunity for the market growth. However, high cost of treatment, high death rate, recalling of some drugs by FDA and lack of proper treatment will hamper the market growth.
Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists, are used to treat high blood pressure and heart failure. They are also used for chronic kidney diseases and prescribed following a heart attack. They include valsartan, losartan and candesartan. If the name of a medicine ends in ‘sartan’, it is an ARB. RBs reduce the action of the hormone angiotensin II. This hormone has a powerful constricting effect on blood vessels, increasing blood pressure. Angiotensin II also stimulates salt and water retention in the body, which further increases blood pressure. ARBs work by blocking receptors that the hormone acts on, specifically AT1 receptors, which are found in the heart, blood vessels and kidneys. Blocking the action of angiotensin II helps to lower blood pressure and prevent damage to the heart and kidneys.
This angiotensin II receptor blockers (ARBs) market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Angiotensin II Receptor Blockers (ARBs) Market Scope and Market Size
Global angiotensin II receptor blockers (ARBs) market is segmented on the basis of type, application and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the angiotensin II receptor blockers (ARBs) market is segmented into azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan.
- On the basis of application, the angiotensin II receptor blockers (ARBs) market is segmented into hypertension, heart Failure, high blood pressure, kidney disease, and others.
- On the basis of end-users, the angiotensin II receptor blockers (ARBs) market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others.
Global Angiotensin II Receptor Blockers (ARBs) Market Country level analysis
Angiotensin II receptor blockers (ARBs) market is analysed and market size information is provided by type, application and end-users as referenced above.
Countries covered in angiotensin II receptor blockers (ARBs) market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherland, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to high technological advancements in healthcare, increasing prevalence and incidence of cardiovascular & kidney disorders, early diagnosis. Europe accounts the second largest market share due to increasing genetic disorders, rare disease and heart blocks. Asia-Pacific is expected to account for the largest market share over coming years for the angiotensin II receptor blockers (ARBs) market due to constant rise in the prevalence and incidence of kidney & cardiovascular disease, and increase in patient population, with increased demand for angiotensin II receptor blockers (ARBs) drugs.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Angiotensin II receptor blockers (ARBs) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Angiotensin II Receptor Blockers (ARBs) Market Share Analysis
Angiotensin II receptor blockers (ARBs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related angiotensin II receptor blockers (ARBs) market.
Major players covered in the angiotensin II receptor blockers (ARBs) market are Daiichi Sankyo Co. Ltd, Lupin Ltd, Novartis AG, Abbvie Inc, Takeda Pharmaceutical Co. Ltd, AstraZeneca, Zydus Cadila., Bristol-Myers Squibb Company among other domestic and global players DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
